433 related articles for article (PubMed ID: 8937862)
1. Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies.
Prueksaritanont T; Gorham LM; Ellis JD; Fernandez-Metzler C; Deluna P; Gehret JR; Strong KL; Hochman JH; Askew BC; Duggan ME; Gilbert JD; Lin JH; Vyas KP
Drug Metab Dispos; 1996 Nov; 24(11):1263-71. PubMed ID: 8937862
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
4. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
[TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
7. Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372. In vivo and in vitro studies in rats, dogs, monkeys, and human.
Prueksaritanont T; Balani SK; Dwyer LM; Ellis JD; Kauffman LR; Varga SL; Pitzenberger SM; Theoharides AD
Drug Metab Dispos; 1995 Jul; 23(7):688-95. PubMed ID: 7587955
[TBL] [Abstract][Full Text] [Related]
8. Analysis of metabolite kinetics by deconvolution and in vivo-in vitro correlations of metabolite formation rates: studies of fibrinogen receptor antagonist ester prodrugs.
Prueksaritanont T; Gorham LM; Yeh KC
J Pharm Sci; 1997 Dec; 86(12):1345-51. PubMed ID: 9423143
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonist.
Fujitaki JM; Cable EE; Ito BR; Zhang BH; Hou J; Yang C; Bullough DA; Ferrero JL; van Poelje PD; Linemeyer DL; Erion MD
Drug Metab Dispos; 2008 Nov; 36(11):2393-403. PubMed ID: 18703645
[TBL] [Abstract][Full Text] [Related]
10. Physiological disposition of L-663,581, a partial agonist of the benzodiazepine receptor, in laboratory animals.
Chen IW; Lin JH
Drug Metab Dispos; 1994; 22(5):693-9. PubMed ID: 7835219
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(N-methoxyamidino)phenyl]furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/antifungal drug DB75 (2,5-bis(4-guanylphenyl)furan dihydrochloride).
Midgley I; Fitzpatrick K; Taylor LM; Houchen TL; Henderson SJ; Wright SJ; Cybulski ZR; John BA; McBurney A; Boykin DW; Trendler KL
Drug Metab Dispos; 2007 Jun; 35(6):955-67. PubMed ID: 17360833
[TBL] [Abstract][Full Text] [Related]
13. A comparison of pharmacokinetics between humans and monkeys.
Akabane T; Tabata K; Kadono K; Sakuda S; Terashita S; Teramura T
Drug Metab Dispos; 2010 Feb; 38(2):308-16. PubMed ID: 19910513
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evaluations of intestinal barriers for the zwitterion L-767,679 and its carboxyl ester prodrug L-775,318. Roles of efflux and metabolism.
Prueksaritanont T; DeLuna P; Gorham LM; Ma B; Cohn D; Pang J; Xu X; Leung K; Lin JH
Drug Metab Dispos; 1998 Jun; 26(6):520-7. PubMed ID: 9616186
[TBL] [Abstract][Full Text] [Related]
15. Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey.
Nishimura T; Amano N; Kubo Y; Ono M; Kato Y; Fujita H; Kimura Y; Tsuji A
Drug Metab Dispos; 2007 Aug; 35(8):1275-84. PubMed ID: 17470527
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey.
Adams WJ; McGovren JP; Dalm EA; Brewer JE; Hosley JD
Cancer Res; 1989 Nov; 49(22):6328-36. PubMed ID: 2529962
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic properties of TDP4815 after single intravenous and oral administrations to rat, rabbit, monkey, dog and in vitro drug metabolism.
Chen Y; Cheng D; Tio C; Kagan N; Eisennagel S; Dasgupta M; Tomczuk B; Bone R; Huebert N
Biopharm Drug Dispos; 2008 Apr; 29(3):127-38. PubMed ID: 18186144
[TBL] [Abstract][Full Text] [Related]
19. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells.
Prueksaritanont T; Gorham LM; Hochman JH; Tran LO; Vyas KP
Drug Metab Dispos; 1996 Jun; 24(6):634-42. PubMed ID: 8781778
[TBL] [Abstract][Full Text] [Related]
20. Disposition of remoxipride in different species. Species differences in metabolism.
Widman M; Nilsson LB; Bryske B; Lundström J
Arzneimittelforschung; 1993 Mar; 43(3):287-97. PubMed ID: 8489555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
